“We are very pleased that this data set has been published,” commented Kevin Gemas, President of Titan Spine. “It clearly illustrates that our surface technology produces a superior environment for bone production over other common interbody fusion implant materials. This data, and others we hope will be published in the future, is helping to change the way spine surgeons and the rest of the spinal community think about interbody fusion implants. No longer should they be thought of as mere interbody spacers, but rather as active participants in the fusion process that promote the body to produce BMP’s naturally and avoid the need for the addition of BMP that was developed externally.”
The abstract of the article, titled, “Osteoblasts exhibit a more differentiated phenotype and increased bone morphogenetic protein production on titanium alloy substrates than on poly-ether-ether-ketone,” can be viewed at http://www.thespinejournalonline.com/article/S1529-9430(12)00091-5/abstract.
About the Company – Titan Spine, LLC is a privately-owned medical implant surface technology company in Mequon, Wisconsin that is focused on the design and manufacturing of proprietary interbody fusion devices for the spine. The company is committed to advancing the science of surface engineering to enhance the treatment of various pathologies of the spine that require fusion. Visit www.titanspine.com to learn more and to view an animation that depicts the cellular response to the company’s surface technology.